Our Mission
Cellectis has decades of expertise in gene editing based on its flagship TALEN® technology
Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment. Leveraging decades of expertise in programmable DNA-binding proteins, the Company has built a differentiated genome engineering platform spanning gene editing, base editing, epigenetic editing and transcriptional regulation. By delivering the genomic intervention each disease requires, Cellectis is advancing a new generation of genetic medicines designed to move beyond disease management and toward lasting therapeutic impact.
Cellectis’ headquarters are in Paris, France, with locations in New York, and Raleigh (NC).
TALEN® is a registered trademark owned by Cellectis.
Editing Life
Here are some of our milestones
Partners
Our partners share our commitment to advancing innovative therapies for patients with significant unmet medical needs around the world